OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Completed · Phase 3 · Has a placebo group

Conditions studied: Hereditary Angioedema

In brief

The purpose of this study was to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsen on the quality and pattern of HAE attacks and their impact on quality of life (QoL).

Key facts

Study ID
NCT05139810
Run by
Ionis Pharmaceuticals, Inc.
People needed
91
Starts
2021-12-03
Expected to finish
2023-11-09
Last updated by the study team
2025-03-06

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.